thymidine has been researched along with HIV-Associated Lipodystrophy Syndrome in 8 studies
HIV-Associated Lipodystrophy Syndrome: Defective metabolism leading to fat maldistribution in patients infected with HIV. The etiology appears to be multifactorial and probably involves some combination of infection-induced alterations in metabolism, direct effects of antiretroviral therapy, and patient-related factors.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The use of nucleoside analogues, especially that of thymidine analogues, depletes mitochondrial DNA, which is the cause of many of the adverse effects of this family of antiretroviral drugs, among them lipodystrophy." | 2.44 | [Tenofovir as a strategy to avoid or limit adverse effects]. ( Portilla, J, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Portilla, J | 1 |
| Miralles Alvarez, C | 1 |
| Ribera Pascuet, E | 1 |
| Curran, A | 1 |
| Tungsiripat, M | 1 |
| Bejjani, DE | 1 |
| Rizk, N | 1 |
| O'riordan, MA | 1 |
| Ross, AC | 1 |
| Hileman, C | 1 |
| Storer, N | 1 |
| Harrill, D | 1 |
| McComsey, GA | 1 |
| Ortiz, M | 1 |
| Poloni, ES | 1 |
| Furrer, H | 1 |
| Kovari, H | 1 |
| Martinez, R | 1 |
| Arnedo, M | 1 |
| Elzi, L | 1 |
| Bernasconi, E | 1 |
| Vernazza, P | 1 |
| Hirschel, B | 1 |
| Cavassini, M | 1 |
| Ledergerber, B | 1 |
| Günthard, HF | 1 |
| Telenti, A | 1 |
| Tarr, PE | 1 |
| Cordery, DV | 1 |
| Martin, A | 2 |
| Amin, J | 1 |
| Kelleher, AD | 1 |
| Emery, S | 1 |
| Cooper, DA | 2 |
| Smith, DE | 1 |
| Carr, A | 1 |
| Law, M | 1 |
| Hudson, J | 1 |
| Hoy, J | 1 |
| Mauss, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Placebo Controlled Study of Rosiglitazone in HIV Lipoatrophy[NCT00367744] | Phase 2 | 71 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Limb fat was measured at baseline and visit week 48 using dual-energy x-ray absorptiometry (DEXA), and change from baseline to week 48 (week 48 - baseline) was estimated for the treatment groups. (NCT00367744)
Timeframe: 48 weeks
| Intervention | grams (Median) |
|---|---|
| Rosiglitazone | 448 |
| Placebo | 153 |
Carotid IMT of the Common carotid artery (CCA) was measured at baseline and week 48, and change from baseline to week 48 (week 48 - baseline) was estimated for the treatment groups. (NCT00367744)
Timeframe: 48 weeks
| Intervention | mm (Median) |
|---|---|
| Rosiglitazone | 0.10 |
| Placebo | 0.15 |
3 reviews available for thymidine and HIV-Associated Lipodystrophy Syndrome
| Article | Year |
|---|---|
[Tenofovir as a strategy to avoid or limit adverse effects].
Topics: Adenine; Anemia; Anti-HIV Agents; Antimetabolites; Clinical Trials as Topic; DNA, Mitochondrial; Dou | 2008 |
[Are all analogue combinations equal?].
Topics: Adenine; Anti-HIV Agents; Antimetabolites; Antiretroviral Therapy, Highly Active; Cardiovascular Dis | 2008 |
[Current role of tenofovir in clinical medicine].
Topics: Adenine; Anti-HIV Agents; Antimetabolites; Antiretroviral Therapy, Highly Active; Chemical and Drug | 2008 |
2 trials available for thymidine and HIV-Associated Lipodystrophy Syndrome
| Article | Year |
|---|---|
Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Cholesterol; Double-Blind Method; Female; HIV Infecti | 2010 |
Thymidine analogue withdrawal for lipoatrophic patients on protease-sparing therapy improves lipoatrophy but compromises antiviral control: the PIILR extension study.
Topics: Anti-HIV Agents; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Middle Aged; Stavudine; Substa | 2002 |
3 other studies available for thymidine and HIV-Associated Lipodystrophy Syndrome
| Article | Year |
|---|---|
No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipoatrophy.
Topics: Adult; Anti-Retroviral Agents; Case-Control Studies; Cohort Studies; DNA, Mitochondrial; Haplotypes; | 2011 |
The influence of HLA supertype on thymidine analogue associated with low peripheral fat in HIV.
Topics: Adenine; Anti-HIV Agents; Australia; Biomarkers; Blood Glucose; Body Fat Distribution; CD4 Lymphocyt | 2012 |
[Prevention and therapy of HIV-associated lipodystrophy syndrome and antiretroviral caused metabolic changes].
Topics: Anti-HIV Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; HIV Infections; HIV Reverse Tra | 2005 |